doi: 10.1056/NEJMc1311039.
Safety profile of extended-release niacin in the AIM-HIGH trial
Affiliations
- PMID: 25014706
- PMCID: PMC4156937
- DOI: 10.1056/NEJMc1311039
Item in Clipboard
Safety profile of extended-release niacin in the AIM-HIGH trial
N Engl J Med.
.
No abstract available
Comment in
-
Niacin and HDL cholesterol--time to face facts.N Engl J Med. 2014 Jul 17;371(3):271-3. doi: 10.1056/NEJMe1406410. N Engl J Med. 2014. PMID: 25014692 No abstract available.
Similar articles
-
Niacin fails to reduce vascular events in large randomised trial.BMJ. 2014 Jul 22;349:g4774. doi: 10.1136/bmj.g4774. BMJ. 2014. PMID: 25055803 No abstract available.
-
Niacin and statin intolerable for some people.Eur Heart J. 2013 Sep;34(33):2579. Eur Heart J. 2013. PMID: 24137778 No abstract available.
-
Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.Indian Heart J. 2008 May-Jun;60(3):215-22. Indian Heart J. 2008. PMID: 19240310
-
Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?J Fam Pract. 2005 Mar;54(3):265-8. J Fam Pract. 2005. PMID: 15755381 Review. No abstract available.
-
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.Vasc Health Risk Manag. 2008;4(5):1001-9. doi: 10.2147/vhrm.s3460. Vasc Health Risk Manag. 2008. PMID: 19183748 Free PMC article. Review.
Cited by
-
Niacin-Induced Syncope in a Middle-Aged Male: When an Over-the-Counter Vitamin Goes Wrong.Cureus. 2023 Dec 13;15(12):e50454. doi: 10.7759/cureus.50454. eCollection 2023 Dec. Cureus. 2023. PMID: 38222212 Free PMC article.
-
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels-Potent Clinical Implications.Pharmaceuticals (Basel). 2023 May 16;16(5):750. doi: 10.3390/ph16050750. Pharmaceuticals (Basel). 2023. PMID: 37242533 Free PMC article. Review.
-
Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.PLoS One. 2022 Jul 1;17(7):e0269531. doi: 10.1371/journal.pone.0269531. eCollection 2022. PLoS One. 2022. PMID: 35776741 Free PMC article.
-
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.Nephrol Dial Transplant. 2023 Mar 31;38(4):982-991. doi: 10.1093/ndt/gfac206. Nephrol Dial Transplant. 2023. PMID: 35751625 Free PMC article. Clinical Trial.
-
Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.Antioxidants (Basel). 2021 Dec 3;10(12):1939. doi: 10.3390/antiox10121939. Antioxidants (Basel). 2021. PMID: 34943043 Free PMC article. Review.
References
-
- The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267. [Erratum, N Engl J Med 2012;367:189.] - PubMed
-
- Armitage J HPS2-THRIVE Collaborative Group. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. ( http://www.hps2-thrive.org/hps2-thrive_ACC_slides.ppt). - PubMed
-
- The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–212. - PubMed
-
- Standarised MedDRA queries. ( http://www.meddra.org/standardised-meddra-queries).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
